Sébahoun G, Gastaut J A, Imbert-Xeridat C, Favre R, Carcassonne Y
Nouv Presse Med. 1979 Feb 24;8(9):663-5.
A trial of immunotherapy in the maintenance treatment of non-lymphoblastic acute leukaemias led to a comparison of 2 groups of patients in complete remission. Group C (14 patients) received only monthly reinduction chemotherapy. Group C + I (17 patients) received identical chemotherapy together with weekly immunotherapy combining BCG and irradiated leukaemic cells. Whilst the duration of the first remission was unmodified, the overall survival and above all survival after the first recurrence were prolonged in group C + I. These results were all the more marked when a homogeneous patients having received the same induction chemotherapy is considered.
一项关于免疫疗法用于非淋巴细胞性急性白血病维持治疗的试验，对两组完全缓解的患者进行了比较。C组（14例患者）仅接受每月一次的再诱导化疗。C + I组（17例患者）接受相同的化疗，同时每周进行一次免疫疗法，将卡介苗和经照射的白血病细胞联合使用。虽然首次缓解的持续时间未改变，但C + I组的总生存期，尤其是首次复发后的生存期延长了。当考虑接受相同诱导化疗的同质患者时，这些结果更为显著。
